Drug designing and development is an important area of research for pharmaceutical
companies and chemical scientists. However, low efficacy, off-target delivery, time …

Post-translational modifications (PTMs) on tau have long been recognized as affecting
protein function and contributing to neurodegeneration. The explosion of information on …

Alzheimer's disease (AD) is the number one neurovegetative disease, but its treatment
options are relatively few and ineffective. In efforts to discover new strategies for AD therapy …

Alzheimer's disease (AD) is the most common form of dementia characterized by presence
of extracellular amyloid plaques and intracellular neurofibrillary tangles composed of tau …

One of the hallmark features in the neurodegenerative disorders (NDDs) is the accumulation
of aggregated and/or non-functional protein in the cellular milieu. Post-translational …

Neurodegenerative diseases like Alzheimer's, Parkinson's and Huntington's disease
involves abnormal aggregation and accumulation of toxic proteins aggregates. Post …

Modern drug design aims to discover novel lead compounds with attractable chemical
profiles to enable further exploration of the intersection of chemical space and biological …

Protein methylation is a key post-translational modification whose effects on gene
expression have been intensively studied over the last two decades. Recently, renewed …

The truncation of Tau is thought to be important in promoting aggregation, with this feature
characterising the pathology of dementias such as Alzheimer disease. Antibodies to the C …

Astrocytes are of vital importance to neuronal function and the health of the central nervous
system (CNS), and astrocytic dysfunction as a primary or secondary event may predispose …